Tumor specific antibody conjugates and uses therefor
US11554181B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 3, 2019 |
| Grant date | Jan 17, 2023 |
| Priority date | — |
| Expiry date | Oct 18, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/41
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are antibodies, and fragments, derivatives, and nanoparticle conjugates thereof, particularly humanized derivatives thereof, which bind to tumor antigens. Also provided are nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind to tumor antigens, polypeptides and CARs encoded by the nucleic acid molecules, vectors and host cells that include the nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered T cells in a subject, expanding a population of genetically engineered T cells in a subject, modulating the amount of cytokine secreted by a T cell, reducing the amount of activation-induced calcium influx into a T cell, providing an anti-tumor immunity to a subject, treating a mammal having a MUC1-associated disease or disorder, stimulating a T cell-mediated immune response to a target cell population or tissue in a subject, and imaging a MUC1-associated tumor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.